B Cell Prolymphocytic Leukemia: 81 Clinical Trials, Page 1 of 9

Hide Studies Not Open or Pending


Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

Condition(s):B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma; B-Cell Prolymphocytic Leukemia; High Grade B-Cell Lymphoma, Not Otherwise Specified; Post-Transplant Lymphoproliferative Disorder; Recurrent Adult Burkitt Lymphoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent Hairy Cell Leukemia; Recurrent Lymphoplasmacytic Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic LymphomaLast Updated:August 2, 2022Active, not recruiting


Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Condition(s):Recurrent Acute Lymphoblastic Leukemia; Recurrent B Acute Lymphoblastic Leukemia; Recurrent B-Cell Prolymphocytic Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent High Grade B-Cell Lymphoma; Recurrent Indolent Non-Hodgkin Lymphoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Transformed Chronic Lymphocytic Leukemia; Refractory Acute Lymphoblastic Leukemia; Refractory B Acute Lymphoblastic Leukemia; Refractory B-Cell Prolymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory High Grade B-Cell Lymphoma; Refractory Indolent Non-Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma; Refractory Transformed Chronic Lymphocytic LeukemiaLast Updated:November 7, 2022Recruiting

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.